<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01712204</url>
  </required_header>
  <id_info>
    <org_study_id>AC-201-GOU-001</org_study_id>
    <nct_id>NCT01712204</nct_id>
  </id_info>
  <brief_title>A Proof-of-Concept Study of AC-201 to Prevent Gout Flares</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Trial Of AC-201 In Subjects With Gout Initiating Urate-Lowering Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TWi Biotechnology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TWi Biotechnology, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Initiation of ULT for gout increases the occurrence of acute gouty arthritis flares due to
      mobilization of urate from tissue deposits. IL-1β plays a key role in mediating the
      inflammatory response in gouty arthritis. The efficacy of IL-1β blockade in the prophylaxis
      of gouty flares during initiation of ULT has been validated in multiple trials of IL-1β
      inhibitor therapies. Therefore, it is believed that IL-1β is a relevant therapeutic target
      for gout flares. AC-201 is an IL-1β modulator indicated for the treatment of osteoarthritis
      with good safety record and very few contraindications to the co-morbidities commonly among
      gout patients. AC-201 has also been demonstrated to have uric acid-lowering effects in
      clinical trials. The favorable product profile of AC-201 overall provides a strong rationale
      for investigating its clinical utility as prophylaxis against flares when initiating ULT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical trials have demonstrated that anti-IL-1 agents (IL-1Ra, IL-1 Trap, and anti-IL-1β
      monoclonal antibody) can reduce the frequency of gout flares during the initial period of
      treatment with urate-lowering therapy and prevent of gout flares in gout patients with
      frequent flares. AC-201 is an oral IL-1 modulator but with a mechanism distinct from that of
      existing anti-IL-1 agents. The active metabolite of AC-201 has been shown in vitro and in
      vivo to inhibit the production and activity of IL-1, down-regulate IL-1 receptors, and
      increase IL1-Ra. Molecular research further suggests that these effects are mediated upstream
      via inhibition of MAPK signaling pathways and binding of NF-κB and AP-1 transcription factors
      that encode for a range of pro-inflammatory factors, including IL-1β, TNF-α, IL-6, IL-8,
      iNOS, and MMPs, which have been implicated in gout flares. AC-201 has also been demonstrated
      to have uric acid-lowering effects in clinical trials. The favorable product profile of
      AC-201 overall provides a strong rationale for investigating its clinical utility as
      prophylaxis against flares when initiating ULT.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Gout Flares Per Subject</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Gout Flares</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo plus Febuxostat</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AC-201</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AC-201 plus Febuxostat</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Capsule BID for 16 Weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>PBO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AC-201</intervention_name>
    <description>AC-201 50mg Capsule BID for 16 Weeks</description>
    <arm_group_label>AC-201</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Febuxostat</intervention_name>
    <description>Febuxostat 80 mg QD for 16 Weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>AC-201</arm_group_label>
    <other_name>ULT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female age 20 to 80 years, inclusive

          -  Meets at least 6 of the 12 American College of Rheumatology preliminary criteria
             (1977) for the classification of acute arthritis of primary gout, OR have proven
             tophus or documented monosodium urate (MSU) crystals in the joint fluid

          -  Serum uric acid ≥7.5 mg/dL at screening

          -  Experienced ≥2 gouty arthritis flares within one year prior to screening

        Exclusion Criteria:

          -  Occurrence of a gouty arthritis flare ongoing at screening or during the screening
             period through baseline

          -  Use of allopurinol, febuxostat, benzbromarone, probenecid, or sulfinpyrazone within 4
             weeks prior to screening

          -  Use of colchicine, glucocorticoids, NSAIDs, or COX-2 inhibitors within 1 week prior to
             screening

          -  Other (non-gout) chronic arthritis, acute inflammatory arthritis, autoimmune diseases
             with arthritis, or any condition requiring chronic daily use of pain medication

          -  History of allergy to any components of study medication, including diacerein

          -  Allergy, contraindication, or intolerance to febuxostat

          -  Contraindication or allergy to NSAIDs

          -  Severe renal impairment

          -  Any prior use of biologic anti-inflammatory therapy, such as IL-1 modulators, tumor
             necrosis factor inhibitors, IL-6 inhibitors, or T-cell costimulation modulator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2012</study_first_submitted>
  <study_first_submitted_qc>October 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2012</study_first_posted>
  <results_first_submitted>November 24, 2014</results_first_submitted>
  <results_first_submitted_qc>November 24, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 1, 2014</results_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prophylaxis of Acute Gout Flares</keyword>
  <keyword>Urate-Lowering Therapy</keyword>
  <keyword>Hyperuricemia</keyword>
  <keyword>Gouty arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gout</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Febuxostat</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Overall, 82 patients from 8 clinical centers participated in the study between 28 January 2013 to 04 September 2013.</recruitment_details>
      <pre_assignment_details>Participants were assessed at an initial screening visit within 2 weeks before the baseline visit.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo Capsule BID for 16 Weeks</description>
        </group>
        <group group_id="P2">
          <title>AC-201</title>
          <description>AC-201 50mg Capsule BID for 16 Weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>A total of 82 subjects were randomized and received at least one dose of study medication (the Intent-to-Treat [ITT] Population). The ITT Population was used for baseline/demographic, disposition, and safety summaries. The ITT Population was the primary analysis set for efficacy analyses.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo Capsule BID</title>
          <description>Placebo Capsule BID for 16 Weeks</description>
        </group>
        <group group_id="B2">
          <title>AC-201 50mg Capsule BID</title>
          <description>AC-201 50mg Capsule BID for 16 Weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="82"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.6" spread="11.8"/>
                    <measurement group_id="B2" value="43.7" spread="12.6"/>
                    <measurement group_id="B3" value="43.6" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Gout Flares Per Subject</title>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo Capsule BID for 16 Weeks
Background therapy: Urate-Lowering Therapy (Febuxostat 80 mg QD)</description>
          </group>
          <group group_id="O2">
            <title>AC-201</title>
            <description>AC-201 50mg Capsule BID for 16 Weeks
Background therapy: Urate-Lowering Therapy (Febuxostat 80 mg QD)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Gout Flares Per Subject</title>
          <units>flares</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.02" lower_limit="2.51" upper_limit="3.64"/>
                    <measurement group_id="O2" value="2.45" lower_limit="2.01" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1356</p_value>
            <method>Possion regression</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.81</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.113</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>16 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo Capsule BID for 16 Weeks
Background therapy: Urate-Lowering Therapy (Febuxostat 80 mg QD)</description>
        </group>
        <group group_id="E2">
          <title>AC-201</title>
          <description>AC-201 50mg Capsule BID for 16 Weeks
Background therapy: Urate-Lowering Therapy (Febuxostat 80 mg QD)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Frequent Gout Attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood CPK increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>ALT increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Creatinine renal clearance decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>TWi Biotechnology, Inc.</organization>
      <phone>+886-2-26573350 ext 368</phone>
      <email>Carl.Brown@twipharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

